{"result": {"id": "5aa3b6ad-4682-4b8c-9c11-4d0da26705fc", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "{\n    \"title\": \"Lipid-Regulating Drugs and Their Interactions\",\n    \"summary\": \"This community focuses on lipid-regulating drugs, primarily from the fibrate and statin classes, and their interactions with other medications. Key entities include Gemfibrozil, Fenofibrate, and Clopidogrel, which are interconnected through their metabolic pathways and potential for adverse drug interactions. The community highlights the importance of understanding these interactions to prevent adverse effects such as muscle toxicity and reduced drug efficacy.\",\n    \"rating\": 7.5,\n    \"rating_explanation\": \"The impact severity rating is high due to the potential for serious adverse effects and drug interactions that can affect patient safety and treatment outcomes.\",\n    \"findings\": [\n        {\n            \"summary\": \"Gemfibrozil's significant drug interactions\",\n            \"explanation\": \"Gemfibrozil, a fibrate drug, is known to inhibit CYP2C8 and UGT enzymes, leading to significant drug interactions with medications like Rosiglitazone, Pioglitazone, and Repaglinide. These interactions can enhance the drug effects or prolong their action, increasing the risk of adverse effects such as hypoglycemia or muscle toxicity. [Data: Entities (3444), Relationships (5232, 5264, 5284)]\"\n        },\n        {\n            \"summary\": \"Fenofibrate's safer profile compared to Gemfibrozil\",\n            \"explanation\": \"Fenofibrate, another fibrate drug, does not inhibit CYP2C8 or UGT enzymes, resulting in fewer drug interactions. This makes Fenofibrate a safer option for patients on multiple medications, especially those requiring drugs metabolized by these enzymes. [Data: Entities (3443), Relationships (3209)]\"\n        },\n        {\n            \"summary\": \"Clopidogrel and proton pump inhibitors interaction\",\n            \"explanation\": \"Clopidogrel's efficacy can be reduced when co-administered with proton pump inhibitors like Omeprazole and Esomeprazole, due to competition for CYP2C19 metabolism. This interaction is clinically significant as it can decrease the antiplatelet effect of Clopidogrel, increasing the risk of thrombotic events. [Data: Relationships (5254, 5312)]\"\n        },\n        {\n            \"summary\": \"Risk of muscle toxicity with statin and fibrate combination\",\n            \"explanation\": \"The combination of statins (e.g., Simvastatin) with fibrates (e.g., Gemfibrozil) increases the risk of muscle toxicity, including rhabdomyolysis. This is due to the pharmacokinetic interactions that elevate statin levels in the blood. [Data: Relationships (5232, 4140)]\"\n        },\n        {\n            \"summary\": \"Repaglinide's interaction with Clopidogrel and Gemfibrozil\",\n            \"explanation\": \"Repaglinide, an oral hypoglycemic agent, has its metabolism inhibited by both Clopidogrel and Gemfibrozil, leading to an increased risk of hypoglycemia. This highlights the need for careful monitoring and dose adjustment when these drugs are used together. [Data: Relationships (5129, 5470)]\"\n        }\n    ]\n}", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1752168556, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 679, "prompt_tokens": 6183, "total_tokens": 6862, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 1728}, "prompt_cache_hit_tokens": 1728, "prompt_cache_miss_tokens": 4455}}, "input": {"messages": [{"content": "\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community's key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            },\n            {\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }\n        ]\n    }\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nLimit the total report length to 2000 words.\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{\n    \"title\": \"Verdant Oasis Plaza and Unity March\",\n    \"summary\": \"The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.\",\n    \"rating\": 5.0,\n    \"rating_explanation\": \"The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.\",\n    \"findings\": [\n        {\n            \"summary\": \"Verdant Oasis Plaza as the central location\",\n            \"explanation\": \"Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza's association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]\"\n        },\n        {\n            \"summary\": \"Harmony Assembly's role in the community\",\n            \"explanation\": \"Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]\"\n        },\n        {\n            \"summary\": \"Unity March as a significant event\",\n            \"explanation\": \"The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community's dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]\"\n        },\n        {\n            \"summary\": \"Role of Tribune Spotlight\",\n            \"explanation\": \"Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]\"\n        }\n    ]\n}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\r\n3444,吉非罗齐,\"吉非罗齐（Gemfibrozil）是一种贝特类药物，主要用于治疗以三酰甘油（甘油三酯）升高为主的高脂血症，通过降低三酰甘油水平发挥作用。作为CYP2C8抑制剂，吉非罗齐会减慢经该酶代谢的药物（如罗格列酮、吡格列酮和瑞格列奈）的代谢，从而可能增强其药效或延长作用时间。此外，吉非罗齐还能抑制尿苷二磷酸葡萄糖醛酸转移酶（UGT），延缓阿托伐他汀的葡萄糖醛酸化代谢，导致阿托伐他汀的血药浓度-时间曲线下面积（AUC）增加，进而升高肌病风险。  \n\n吉非罗齐与辛伐他汀合用时，会显著增加辛伐他汀的AUC和峰浓度（Cmax），可能引发肌肉毒性，表现为肌酸激酶升高和肌病。因此，临床使用吉非罗齐时需注意药物相互作用，尤其是与他汀类或其他经CYP2C8或UGT代谢的药物联用，以避免不良反应。  \n\n综上所述，吉非罗齐是一种有效的降三酰甘油药物，但其药代动力学特性可能导致多种药物相互作用，需在医生指导下谨慎使用。\",17\r\n3443,非诺贝特,\"**非诺贝特**是一种贝特类药物，化学名称为普鲁脂芬，商品名包括立平脂、苯酰降酯内酯等，主要用于降脂治疗，尤其适用于以三酰甘油（甘油三酯）升高为主的高脂血症。作为治疗高三酰甘油血症的首选药物，其作用机制主要为显著降低血液中的三酰甘油水平。  \n\n非诺贝特的常规剂量为0.1克/次，每日2次，但停药后可能出现血脂反弹现象。该药物不良反应较少，但部分患者可能出现胃肠道不适、食欲减退、嗳气、皮疹、白细胞减少或暂时性肝转氨酶升高等症状。相较于其他降脂药物，非诺贝特对UGT（尿苷二磷酸葡萄糖醛酸转移酶）和CYP2C8（细胞色素P450 2C8酶）无抑制作用，因此药物相互作用极少见，临床安全性较高。  \n\n综合来看，非诺贝特是一种高效且耐受性良好的降脂药物，尤其适用于三酰甘油升高的患者，但需注意其潜在不良反应及停药后可能出现的血脂反弹问题。\",13\r\n4962,西立伐他汀,西立伐他汀是一种他汀类药物，与吉非罗齐联用有致横纹肌溶解的报道>,1\r\n4977,肌酸激酶,,1\r\n4982,葡萄糖醛酸,葡萄糖醛酸是一种物质，与辛伐他汀酸结合后被吉非罗齐抑制>,1\r\n3579,贝特类,\"**贝特类**（Fibrates）是一类主要用于调节血脂的药物，属于降脂药物中的重要分支。其主要成分包括吉非贝齐（gemfibrozil）和非诺贝特（fenofibrate）等。这类药物的核心作用是显著降低血液中的三酰甘油（triglyceride）水平，同时能够升高高密度脂蛋白（HDL），从而改善血脂代谢异常。  \n\n贝特类药物在临床上常用于治疗高三酰甘油血症（hypertriglyceridemia），尤其适用于以三酰甘油升高为主的脂代谢紊乱患者。此外，它们也可能与其他降脂药物（如他汀类）联合使用，以协同调节血脂水平。然而，联合用药时需谨慎，因为可能增加不良反应的风险，如肌肉毒性或肝功能异常。  \n\n总体而言，贝特类药物是一类高效的血脂调整药物，尤其适用于特定类型的高脂血症患者，但在使用过程中需严格遵循医嘱，监测潜在副作用，以确保安全性和疗效。\",7\r\n3591,环丙贝特,\"环丙贝特是一种苯氧芳酸类（或贝特类）药物，主要用于调节血脂，特别是治疗高甘油三酯血症（高TG血症）。作为贝特类药物的一种，环丙贝特通过激活过氧化物酶体增殖物激活受体（PPAR）来降低血液中的甘油三酯水平，同时可能对胆固醇代谢产生调节作用。其药理作用与其他贝特类药物相似，适用于血脂异常患者，尤其是以甘油三酯升高为主要特征的患者。  \n\n环丙贝特的临床应用侧重于改善脂质代谢紊乱，但其具体作用机制和适应症可能因个体情况而有所差异。综合来看，该药物在降血脂领域具有明确疗效，尤其针对高TG血症患者。\",3\r\n4889,氯吡格雷,,11\r\n4882,瑞格列奈,\"瑞格列奈（Repaglinide）是一种口服降糖药，属于格列奈类药物，主要用于治疗2型糖尿病。它通过刺激胰腺β细胞释放胰岛素来降低血糖水平。瑞格列奈的代谢主要依赖于肝脏中的细胞色素P450酶系统，特别是CYP2C8和CYP3A4酶。  \n\n值得注意的是，瑞格列奈与某些药物合用时可能增加低血糖风险。例如，与氯吡格雷（一种抗血小板药物）或吉非罗齐（一种降脂药）联合使用时，可能因药物相互作用而增强瑞格列奈的降糖效果，从而引发低血糖。因此，临床使用时应密切监测血糖水平，必要时调整剂量以避免不良反应。  \n\n综上所述，瑞格列奈是一种经CYP2C8和CYP3A4代谢的降糖药，其疗效和安全性可能受合并用药影响，尤其是与氯吡格雷或吉非罗齐联用时需格外谨慎。\",4\r\n3897,氯贝特,氯贝特是一种药物，也称为氯贝丁酯、氯苯丁酯、安妥明、降脂乙脂、祛脂乙酯、冠心平，用于降脂治疗，可能引起胃肠道不适、白细胞减少、斑状脱发、头昏、皮疹、肝功能异常、肌无力、肌痉挛、胸痛等不良反应,1\r\n3022,吉非贝齐,\"吉非贝齐（诺衡）是一种苯氧芳酸类（或贝特类）药物，主要用于调节血脂，治疗高三酰甘油血症和混合型高脂血症。作为贝特类药物的代表之一，其标准剂量通常为每次0.6克，每日两次。尽管不同描述中对其药物分类的表述略有差异（如“贝特类”或“苯氧芳酸类”），但两者本质一致，因苯氧芳酸衍生物是贝特类药物的主要化学结构。该药物的核心适应症与用法在描述中保持一致，强调了其在血脂异常管理中的作用。  \n\n（注：总字数符合500字限制，内容整合了分类、用途、剂量及术语差异的澄清。）\",5\r\n3020,苯扎贝特,苯扎贝特（必降脂）是一种苯氧芳酸类（或称贝特类）药物，主要用于治疗高三酰甘油血症（高TG血症）和混合型高脂血症，尤其适用于伴有血凝倾向增高的患者。作为血脂调节药物，苯扎贝特通过降低血液中的三酰甘油水平发挥作用。其典型剂量为0.2克，每日服用3次。尽管不同描述中对其分类存在细微差异（如“贝特类药物”与“苯氧芳酸类药物”），但二者本质一致，均指向同一药理类别。该药物在临床中广泛应用于血脂异常管理，尤其针对以三酰甘油升高为主的代谢紊乱。,8\r\n4895,罗格列酮,罗格列酮是一种药物，主要经CYP2C8代谢,4\r\n4900,CYP2C8,\"**CYP2C8** is a liver enzyme primarily involved in the metabolism of various drugs, including **rosiglitazone** and **repaglinide**. As a key metabolic enzyme, it plays a significant role in drug processing, and its activity can be influenced by inhibitors and inducers. Notably, **gemfibrozil metabolites** are known to inhibit CYP2C8, which can lead to a substantial slowdown in the metabolism of drugs processed by this enzyme. This inhibition has clinical implications, particularly for medications like repaglinide, where altered metabolism may affect drug efficacy and safety.  \n\nCYP2C8 is recognized for its broad involvement in the metabolism of multiple pharmaceuticals, though specific inhibitors and inducers beyond gemfibrozil are not detailed in the provided descriptions. The enzyme's function is consistent across different sources, with no major contradictions in its role or interactions. Additionally, it is referenced in both English and Chinese contexts (as \"\"CYP2C8是一种代谢酶，参与多种药物的代谢\"\"), further confirming its widespread recognition in drug metabolism.  \n\nIn summary, **CYP2C8** is a critical hepatic enzyme responsible for metabolizing several drugs, with its activity modifiable by inhibitors such as gemfibrozil metabolites. Understanding its function and interactions is essential for predicting drug behavior and optimizing therapeutic outcomes.\",9\r\n4896,吡格列酮,吡格列酮是一种药物，主要经CYP2C8代谢,4\r\n4967,艾司奥美拉唑,\"艾司奥美拉唑是一种质子泵抑制剂，能与氯吡格雷竞争CYP2C19和CYP3A4的代谢，影响氯吡格雷的活性。\"\"\",2\r\n3590,阿西莫司,\"阿西莫司（又称氧甲吡嗪、乐脂平）是一种烟酸类降脂药物，主要用于治疗高三酰甘油血症、混合型高脂血症以及高胆固醇血症。该药物特别适用于糖尿病继发的血脂异常患者，通过调节血脂水平发挥作用。其常见剂量为250毫克（标注中“园援圆缘克”为“250克”的误写，实际应为毫克单位）。  \n\n作为烟酸衍生物，阿西莫司通过抑制脂肪组织分解、减少游离脂肪酸释放，从而降低肝脏极低密度脂蛋白（VLDL）的合成，最终达到降低三酰甘油和胆固醇的效果。不同描述中提到的适应症（如高三酰甘油血症、混合型高脂血症、高胆固醇血症）并无矛盾，而是反映了其多靶点作用机制。别称“乐脂平”为商品名，“氧甲吡嗪”则为化学名或通用名变体。  \n\n综上，阿西莫司是一种多效降脂药，核心功能涵盖血脂异常的主要类型，尤其针对糖尿病相关代谢紊乱，临床使用需遵循具体剂量规范。\",4\r\n4968,兰索拉唑,\"兰索拉唑是一种质子泵抑制剂，可选择作为与氯吡格雷合用的替代药物。\"\"\",1\r\n4969,泮托拉唑,\"泮托拉唑是一种质子泵抑制剂，可选择作为与氯吡格雷合用的替代药物。\"\"\",1\r\n4970,雷贝拉唑,\"雷贝拉唑是一种质子泵抑制剂，可选择作为与氯吡格雷合用的替代药物。\"\"\",1\r\n4091,肌溶解症,\"肌溶解症是一种严重不良反应，可能由他汀类或贝特类药物引起\"\"\",2\r\n3577,吉非贝特,\"A fibrate drug used to lower triglycerides, also known as Fenofibrate\"\"\",2\r\n3872,诺衡,\"诺衡是一种贝特类药物，用于降低三酰甘油，是治疗高三酰甘油血症的首选药物\"\"\",2\r\n3880,经皮冠状动脉成形术,经皮冠状动脉成形术（PTCA）是一种心脏手术，相关病人需要特殊降脂治疗。,1\r\n3898,阿昔莫司,阿昔莫司是一种药物，也称为乐脂平、吡莫酸、氧甲吡嗪，用于降脂治疗，可能引起皮肤红斑、热感和瘙痒，偶见有上腹部不适、头痛、乏力等不良反应,2\r\n3858,泛硫乙胺,泛硫乙胺又名“潘特生”，其调节血脂的能力是中等度的，与阿西莫司（乐脂平）及益多酯（特调脂）调节血脂的幅度相近似。泛硫乙胺突出优点是不良反应少而轻，对肝、肾功能未见有害作用，且停药后员个月，仍能保持明显的调节血脂的效果。,4\r\n3859,弹性酶,\"弹性酶（Elastase）是一种用于治疗轻度高胆固醇血症的药物，由胰脏提取或通过微生物发酵产生。它是一种易溶解的弹性蛋白酶，由多个氨基酸组成的多肽，分子量约为圆缘怨（具体数值需核实）。弹性酶通过抑制胆固醇的合成并促进其转化为胆酸，从而有效降低血清总胆固醇水平。此外，该药物还具有抗动脉粥样硬化和抗脂肪肝的作用。  \n\n弹性酶的剂型包括胶囊、肠溶片和肠溶丸，推荐剂量为每次30微克，每日服用3次。它适用于除纯合子家族性高胆固醇血症以外的其他类型高胆固醇血症患者。  \n\n综上所述，弹性酶是一种多功能的降胆固醇药物，兼具调节血脂和改善血管健康的作用，临床主要用于非遗传性高胆固醇血症的治疗。\",2\r\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,combined_degree\r\n3210,吉非罗齐,高脂血症,吉非罗齐用于治疗以三酰甘油升高为主的高脂血症。,251\r\n3209,非诺贝特,高脂血症,非诺贝特用于治疗以三酰甘油升高为主的高脂血症。,247\r\n5232,吉非罗齐,西立伐他汀,吉非罗齐与西立伐他汀联用有致横纹肌溶解的报道,18\r\n5264,吉非罗齐,肌酸激酶,吉非罗齐可能导致肌酸激酶升高,18\r\n5284,吉非罗齐,葡萄糖醛酸,吉非罗齐抑制辛伐他汀酸与葡萄糖醛酸的结合,18\r\n3875,贝特类,他汀类,他汀类和贝特类药物可以联合应用治疗混合性高脂血症,16\r\n4819,非诺贝特,环丙贝特,非诺贝特和环丙贝特都是贝特类药物，主要用于治疗高TG血症,16\r\n5254,氯吡格雷,奥美拉唑,\"氯吡格雷（Clopidogrel）是一种抗血小板药物，常用于预防血栓形成，而奥美拉唑（Omeprazole）是一种质子泵抑制剂，用于治疗胃酸相关疾病。两者在代谢过程中存在相互作用，可能影响氯吡格雷的疗效。  \n\n研究表明，奥美拉唑会与氯吡格雷竞争肝脏中的CYP2C19和CYP3A4酶代谢途径。由于氯吡格雷是一种前药，需要通过CYP2C19代谢活化才能发挥抗血小板作用，而奥美拉唑同样依赖该酶进行代谢，因此可能减少氯吡格雷的活化，降低其抗血栓效果。这一相互作用已被多项临床观察和药代动力学研究证实。  \n\n尽管部分研究指出CYP3A4也可能参与两者的代谢竞争，但CYP2C19的抑制作用被认为是主要机制。因此，对于需要同时使用氯吡格雷和奥美拉唑的患者，临床医生可能会考虑调整用药方案，例如选择对CYP2C19影响较小的替代抑酸药物（如泮托拉唑），或监测氯吡格雷的抗血小板效果，以确保治疗的有效性和安全性。  \n\n综上，奥美拉唑与氯吡格雷的代谢竞争可能削弱后者的疗效，这一相互作用在临床用药中需予以重视。\",16\r\n5129,瑞格列奈,氯吡格雷,\"瑞格列奈与氯吡格雷合用时存在显著的药物相互作用风险。氯吡格雷可能显著提高瑞格列奈的血药浓度，从而增加低血糖的发生概率。这一相互作用机制表明，两者联合使用需谨慎，并密切监测血糖水平以避免不良反应。  \n\n综合现有信息，瑞格列奈（一种快速作用的胰岛素促泌剂）与氯吡格雷（一种抗血小板药物）的联用可能导致协同效应，进一步加剧低血糖风险。因此，临床使用时应评估患者个体情况，必要时调整剂量或采取预防措施。\",15\r\n3933,氯贝特,非诺贝特,氯贝特和非诺贝特都是降脂药物，具有相似的不良反应和禁忌症,14\r\n3936,吉非贝齐,苯扎贝特,吉非贝齐和苯扎贝特都是降脂药物，具有相似的不良反应和禁忌症,13\r\n5142,罗格列酮,CYP2C8,罗格列酮主要经CYP2C8代谢,13\r\n5145,吡格列酮,CYP2C8,吡格列酮主要经CYP2C8代谢,13\r\n5312,艾司奥美拉唑,CYP2C19,\"Esomeprazole competes with clopidogrel for CYP2C19 metabolism, reducing clopidogrel's efficacy\",13\r\n5470,CYP2C8,瑞格列奈,瑞格列奈 is metabolized by CYP2C8,13\r\n3893,阿西莫司,苯扎贝特,\"阿西莫司和苯扎贝特是两种用于治疗代谢性疾病的药物，主要针对高三酰甘油血症和混合型高脂血症，尤其适用于继发于糖尿病的患者。这两种药物均具有降低空腹血糖的作用，同时也能有效调节血脂水平，改善患者的代谢状况。  \n\n阿西莫司和苯扎贝特的作用机制虽不完全相同，但均能通过不同的途径减少血液中的三酰甘油含量，从而降低心血管疾病的风险。此外，它们对糖尿病患者的血糖控制也有辅助效果，使其成为治疗糖尿病相关脂代谢异常的重要选择。  \n\n综合来看，阿西莫司和苯扎贝特在临床应用中既可用于调节血脂，又能改善血糖水平，尤其适合同时患有高脂血症和糖尿病的患者。\",12\r\n5256,氯吡格雷,兰索拉唑,兰索拉唑可作为与氯吡格雷合用的替代药物。,12\r\n5257,氯吡格雷,泮托拉唑,泮托拉唑可作为与氯吡格雷合用的替代药物。,12\r\n5258,氯吡格雷,雷贝拉唑,氯吡格雷（Clopidogrel）是一种抗血小板药物，常用于预防血栓形成，而雷贝拉唑（Rabeprazole）是一种质子泵抑制剂（PPI），主要用于治疗胃酸相关疾病。研究表明，雷贝拉唑对氯吡格雷活性代谢物的血药浓度-时间曲线下面积（AUC）影响较小，因此两者合用时安全性较高。相较于其他PPIs，雷贝拉唑可作为与氯吡格雷联合用药的替代选择，减少潜在的药物相互作用风险。这一结论得到了中文和英文描述的一致支持，强调了雷贝拉唑在临床合用中的优势。,12\r\n4140,他汀类,肌溶解症,他汀类药物可能引起肌溶解症,11\r\n3489,吉非贝特,贝特类,Fenofibrate belongs to the fibrate class of drugs,9\r\n3874,诺衡,贝特类,诺衡属于贝特类药物,9\r\n3895,苯扎贝特,经皮冠状动脉成形术,苯扎贝特可用于经皮冠状动脉成形术后病人的降脂治疗,9\r\n3935,阿昔莫司,吉非贝齐,阿昔莫司和吉非贝齐都是降脂药物，具有相似的不良反应和禁忌症,7\r\n3849,泛硫乙胺,弹性酶,Both are drugs used for regulating blood lipids,6\r\n\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            },\n            {\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }\n        ]\n    }\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nLimit the total report length to 2000 words.\n\nOutput:", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": null, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0, "response_format": {"type": "json_object"}}}, "key": "chat_create_community_report_0e047a3a3ac46e95fd01c6653f09880e84a0fe13c565a8e05b5847082d143c6c_v2"}